Clinical Trial

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-20.
Status change: Recruiting → Active, Not Recruiting 2026-01-25
Trial Details
NCT Number NCT05300932
Lead Sponsor Tongji Hospital
Collaborators: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Eli Lilly and Company, Johns Hopkins University
Conditions Systemic Sclerosis
Enrollment 60 participants
Start Date 2022-03-08
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-11-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-27